康希諾生物公司的COVID-19候選疫苗在中國獲准用於軍事用途

Yahoo News on 29 June 2020 reported the following:

CanSino's COVID-19 vaccine candidate approved for military use in China

Reuters Reuters 11 hours ago

Reactions Reblog on Tumblr Share Tweet Email

BEIJING (Reuters) - China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics <6185.HK> after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).

"The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department," CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

CanSino declined to disclose whether the innoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

The military approval follows China's decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The Phase 1 and 2 clinical trials of the CanSino's vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received an approval earlier this month to test its second experimental coronavirus vaccine in humans.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

Translation

北京（路透社）- 康希諾生物股份公司<6185.HK>週一表示, 在經過臨床試驗證明它們的疫苗是安全的, 並顯示出一定功效之後，中國軍方已經獲得許可開始使用由軍方研究部門和該公司開發的COVID-19候選疫苗。

針對由新型冠狀病毒引起的呼吸系統疾病的候選疫苗Ad5-nCoV是中國批准的國內外八項人體試驗的候選疫苗之一。該疫苗還獲得了加拿大人體測試的批准。

康希諾在一份文件中說，中國中央軍事委員會於6月25日批准了該疫苗的使用，有效期為一年。候選疫苗是由康希諾和軍事科學研究院（AMS）研究所共同開發。

康希諾跟據批准軍隊使用疫苗的中央軍事委員會部說: "Ad5-nCoV目前僅限於軍事用途, 未經後勤保障部批准, 其使用範圍不能擴大到更廣泛的接種範圍" 。

 康希諾在給路透社的一封電子郵件中, 以商業秘密為理由, 拒絕透露候選疫苗的接種是強制性還是自願選擇的。

這軍方批准是繼中國在本月早些時候決定向出國旅行的國有企業的僱員提供另外兩名候選疫苗的決定之後作出。

 該公司表示，康希諾候選疫苗的1期和2期臨床試驗表明，它具有預防冠狀病毒引起疾病的潛力，該冠狀病毒已在全球殺死了半百萬人，但不能保證其商業上將會成功。

 另外，AMS已於本月初獲得批准，可以在人類中進行其第二輪實驗性冠狀病毒疫苗測試。

目前尚無針對這種新型冠狀病毒引起的疾病的疫苗被批准用於商業用途，但是來自全球100多個候選者的十幾種疫苗, 正在於人體中進行測試。

              So, it seems that soon we shall have a choice to pick a vaccine manufactured by different countries.